Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.42 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13275222 | 0.94 | PARP1 (0.38) | PARP1METRIPK1LMNACNR2 | |
| SCHEMBL13274731 | 0.91 | PARP1 (0.38) | PARP1RIPK1LMNAKMT2AMEN1 | |
| SCHEMBL13274666 | 0.91 | LMNA (0.37) | PARP1LMNA | |
| SCHEMBL13275408 | 0.90 | ELOVL1 (0.44) | PARP1 | |
| SCHEMBL13274891 | 0.89 | ELOVL1 (0.45) | PARP1LMNAKMT2AMEN1 | |
| SCHEMBL13274908 | 0.89 | LMNA (0.38) | PARP1RIPK1LMNAKMT2AMEN1 | |
| SCHEMBL13449275 | 0.88 | MET (0.54) | PARP1METLMNA | |
| SCHEMBL13274992 | 0.88 | LMNA (0.39) | PARP1LMNAKMT2AMEN1 | |
| SCHEMBL13275058 | 0.86 | LMNA (0.41) | PARP1RIPK1LMNAKMT2AMEN1 | |
| SCHEMBL13275323 | 0.86 | PARP1 (0.41) | PARP1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | claimed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | claimed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | claimed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | PARP1 2307/4885MET 2/4885HDAC3 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.